Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
hair games
Popular Articles
Cellulite Treatment

Disparity In Sex Ratio Increases In Vietnam
Sex-selective abortion among families in Vietnam with a cultural preference for boys has contributed to a sex ratio of 112 male infant births for every 100 female births in the country, according to a government official, the AP/Yahoo! News reports. According to the AP/Yahoo! News, many doctors in Vietnam do not comply with a 2003 law prohibiting the disclosure of a fetus" sex. Duong Quoc Trong, deputy director of the General Office for Population and Family Planning, said that the birth rate in 1999 was considered close to the natural rate, with about 107 boys born for every 100 girls. Since 2006, the ratio of boys to girls has steadily increased and approached a rate similar to China"s imbalance 20 years ago, he said.Trong added that the government intends to more strictly enforce the country"s ban on sex-selective abortion. The Ministry of Health recently confiscated more than 2,600 books that claim to describe ways to conceive a male child, such as special diets, MOH Deputy Chief Inspector Nguyen Dingh Bach said. He added that the ministry also ordered seven Web sites to remove articles describing such methods (AP/Yahoo! News, 7/2).
generic viagra online
A Step Closer To Drugs Against Winter Vomiting Disease
The virus that causes winter vomiting disease invades cells by attaching to particular sugar molecules on the surface of the cells. This is the conclusion of a thesis presented at the Sahlgrenska Academy, University of Gothenburg, Sweden. This result may be an important step in the development of a drug against the regular hospital-based epidemics caused by the virus.
News of the day
Mayo Clinic Cancer Center Support Grant Renewed By NCI, Comprehensive Status Extended
The Mayo Clinic Cancer Center (MCCC) received an additional five years of National Cancer Institute (NCI) funding and re-designation as a comprehensive cancer center, according to Robert Diasio, M.D., the center"s director. Mayo Clinic has the only NCI-designated comprehensive cancer center conducting research at three distinct locations across the United States.
Public Health

BioCis Pharma Starts A Phase I Clinical Trial With A New Cancer Drug

BioCis Pharma Ltd., a privately-held drug development company with its headquarters in Turku, Finland, has started Phase I clinical testing of ProtoCure(TM) intravesical instillation solution, a novel anti-cancer drug for urinary bladder cancer. ProtoCure is based on a new mechanism of action discovered and developed by BioCis Pharma which effectively prevents cancer growth and proliferation locally. The open-label, dose-escalating study is designed to evaluate the safety, tolerability and pharmacokinetics of the locally administered (into the bladder) product in a total of 22 patients with primary or recurrent non-muscle invasive bladder cancer and it is expected to be well tolerated. "We are pleased to advance to clinical testing with the ProtoCure instillation solution," says Lasse Leino, CEO of BioCis Pharma. "It is our first oncology product to reach this important milestone and follows the initiation of two phase 2a studies with our leading anti-inflammatory product in patients with inflammatory skin disorders that we recently announced. The ProtoCure cancer drug holds great promise for patients suffering from superficial bladder cancer. We are committed to take the product quickly to more extensive clinical efficacy testing after this preliminary safety study. We expect to get results from this study by the first quarter of 2010." Bladder cancer is the fourth most common cancer in men and tenth among women. In addition, the recurrence rate is high, being almost 70 % in patients with the non-invasive form of the cancer, where the malignancy is typically found in the surface layers of the bladder. Non-invasive bladder cancer is treated by urologists using local surgery and intravesical drug therapy administered directly into the bladder. Existing drug therapies often have undesirable side effects and limited efficacy. BioCis Pharma Ltd is an innovative drug development company developing drug therapies based on a novel, patented therapeutic principles that target unmet medical needs in substantial therapeutic markets including inflammation, allergy, and cancer. The company"s main investors are Karolinska Development AB (publ.), Finnish Industry Investment Ltd., and Etra Invest Oy. BioCis Pharma Ltd


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009